Propanc Biopharma, Inc. (PPCB): Total Liabilities
$3.38M
As of 2026-06-30
$3.26M
As of 2026-09-30
+2.1%
3-year compound annual growth
+1.9%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2026-06-30 | $3.38M | -41.0% | 2026-09-25, Balance as of period end |
| 2025-06-30 | $5.73M | +48.7% | 2026-09-25, Balance as of period end |
| 2024-06-30 | $3.85M | +21.2% | 2025-09-29, Balance as of period end |
| 2023-06-30 | $3.18M | +2.3% | 2024-09-30, Balance as of period end |
| 2022-06-30 | $3.11M | +0.8% | 2023-09-28, Balance as of period end |
| 2021-06-30 | $3.08M | -17.6% | 2022-09-28, Balance as of period end |
| 2020-06-30 | $3.74M | -15.1% | 2021-09-28, Balance as of period end |
| 2019-06-30 | $4.40M | n/a | 2020-10-01, Balance as of period end |
| No annual figure between 2012-06-30 and 2019-06-30. | |||
| 2012-06-30 | $584.2K | +90.4% | 2012-10-15, Balance as of period end |
| 2011-06-30 | $306.8K | n/a | 2012-10-15, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Propanc Biopharma, Inc. (PPCB) | 2026-06-30 | $3.38M | -41.0% |
| Nomad Power Solutions, Inc. (NMAD) | 2025-12-31 | $1.77M | +456.8% |
| PMGC Holdings Inc. (ELAB) | 2025-12-31 | $5.03M | +115.6% |
| NRX Pharmaceuticals, Inc. (NRXP) | 2025-12-31 | $28.89M | +7.5% |
| Imunon, Inc. (IMNN) | 2025-12-31 | $5.23M | -4.5% |
| Turn Therapeutics Inc. (TTRX) | 2025-12-31 | $7.48M | +235.8% |
| CalciMedica, Inc. (CALC) | 2025-12-31 | $20.23M | +275.8% |
| PRF Technologies Ltd. (PRFX) | 2025-12-31 | $2.71M | +0.3% |
| Chemomab Therapeutics Ltd. (CMMB) | 2025-12-31 | $1.48M | -56.9% |
Compare PPCB, NMAD, ELAB, NRXP side by side · Screen every company in Pharmaceutical Preparations ↗